title: Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
abstract: OBJECTIVE
  An overrepresentation of a fast peritoneal transport status in new peritoneal dialysis (PD) patients with extensive comorbidity has been reported in some studies. High mass transfer area coefficients (MTACs) of low MW solutes suggest the presence of a large effective peritoneal surface area. The mechanism is unknown. It might include comorbidity, chronic inflammation, or an effect of mesothelial cell mass on peritoneal transport by the production of vasoactive substances. To investigate their relative importance in early PD, peritoneal permeability characteristics in incident PD patients were analyzed for relationships with comorbidity, serum concentrations of inflammatory markers, and products of the mesothelial cells that can be detected in dialysate.
  
  
  METHODS
  A cross-sectional study.
  
  
  METHODS
  A university hospital.
  
  
  METHODS
  46 patients who fulfilled the following inclusion criteria were analyzed: a standard peritoneal permeability analysis (SPA) within 6 months after the start of PD, no peritonitis prior to the SPA, older than 18 years, and without diabetes mellitus as a primary renal disease. The patients were divided into tertiles based on the MTAC creatinine: slow, medium, and fast transport groups. The Davies comorbidity score was used to assess comorbidity. Serum and dialysate samples obtained during the SPA were used to determine hyaluronan, interleukin (IL)-6, vascular endothelial growth factor (VEGF), and cancer antigen 125 (CA125). The dialysate concentrations of these substances were expressed as their dialysate appearance rates.
  
  
  RESULTS
  No significant differences were present in the three transport groups for comorbidity, serum concentrations of inflammatory markers, or serum VEGF. Interleukin-6 and VEGF concentration attributed to local VEGF production were not different between the tertiles. Levels of VEGF were higher in the medium transport group compared to the slow transport group (p = 0.02); CA125 was higher in the fast transport group compared to the medium transport group (p= 0.01). When analyzed as continuous variables, MTAC creatinine was related to VEGF (r= 0.33, p < 0.05) and CA125 (r= 0.41, p = 0.03). In linear regression analysis, VEGF influenced the association between CA125 and MTAC creatinine; IL-6 weakened this association only marginally.
  
  
  CONCLUSIONS
  A fast peritoneal transport status in incident nondiabetic PD patients was not related to comorbidity. The relationships found between VEGF, CA125, and MTAC creatinine may suggest a role of VEGF in the regulation of the vascular peritoneal surface area, possibly already before structural abnormalities have developed. Our analyses are consistent with the hypothesis that mesothelial cell mass is an important determinant of the peritoneal transport status in incident nondiabetic PD patients without previous peritonitis. Of the many potential mediators produced by mesothelial cells, VEGF was more important than the inflammation marker IL-6.
authors.affiliation: Department of Nephrology, Academic Medical Center, University of Amsterdam, The Netherlands.
authors.forename: Sadie
authors.initials: S
authors.lastname: van Esch
authors.forename: Machteld M
authors.initials: MM
authors.lastname: Zweers
authors.forename: Maarten A M
authors.initials: MA
authors.lastname: Jansen
authors.forename: Dirk R
authors.initials: DR
authors.lastname: de Waart
authors.forename: Jeannette G
authors.initials: JG
authors.lastname: van Manen
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Krediet
mesh_terms: D001692:Biological Transport / Q000502:physiology*; D015415:Biomarkers / Q000032:analysis*; D018394:CA-125 Antigen / Q000032:analysis; D015897:Comorbidity; D003404:Creatinine / Q000032:analysis; D003430:Cross-Sectional Studies; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D015850:Interleukin-6 / Q000032:analysis; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010537:Peritoneum / Q000502:physiology; D010539:Permeability; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis
chemical_list: D015415:Biomarkers; D018394:CA-125 Antigen; D015314:Dialysis Solutions; D015850:Interleukin-6; D042461:Vascular Endothelial Growth Factor A; D006820:Hyaluronic Acid; D003404:Creatinine